NEJM: Brentuximab Vedotin (SGN-35) for recurrent CD30-positive lymphoma
Hodgkin's lymphoma and anaplastic large cell lymphoma are the two most common tumors expressing CD30. Monoclonal techniques previously targeting the CD30 antigen, method of treatment of tumor, but the method is very weak anti-tumor activity. CD30 targeted therapies to enhance the anti-tumor activity, connected through one kind of cleavage enzyme (enzyme-cleavable linker) to anti-microtubule drugs monomethyl auristatin E (MMAE) and CD30-specific monoclonal antibody coupled to produce antibody drug conjugates --- matter brentuximab vedotin (SGN-35).
NEJM: Brentuximab Vedotin (SGN-35) for recurrent CD30-positive lymphoma
ReplyDeleteHodgkin's lymphoma and anaplastic large cell lymphoma are the two most common tumors expressing CD30. Monoclonal techniques previously targeting the CD30 antigen, method of treatment of tumor, but the method is very weak anti-tumor activity. CD30 targeted therapies to enhance the anti-tumor activity, connected through one kind of cleavage enzyme (enzyme-cleavable linker) to anti-microtubule drugs monomethyl auristatin E (MMAE) and CD30-specific monoclonal antibody coupled to produce antibody drug conjugates --- matter brentuximab vedotin (SGN-35).
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
ABT-737
Nutlin-3a chiral
p53 and MDM2 proteins-interaction-inhibitor
Serdemetan
Nutlin-3b
Nutlin-3
p53 and MDM2 proteins-interaction-inhibitor chiral
p53 and MDM2 proteins-interaction-inhibitor (racemic)
YM-155
Pomalidomide